Fluoroazomycin arabinoside F-18
- Generic Name
- Fluoroazomycin arabinoside F-18
- Drug Type
- Small Molecule
- Chemical Formula
- C8H10FN3O5
- CAS Number
- 864084-85-5
- Unique Ingredient Identifier
- UG7I3Y42PV
- Background
Fluoroazomycin arabinoside F-18 is under investigation in clinical trial NCT03257150 (A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer).
FAZA PET/MRI Pancreas
Not Applicable
Active, not recruiting
- Conditions
- Locally Advanced Pancreatic AdenocarcinomaUnresectable Pancreatic CancerPancreatic Adenocarcinoma Non-resectable
- First Posted Date
- 2020-05-20
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 20
- Registration Number
- NCT04395469
- Locations
- 🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
FAZA PET/MRI Sarcoma
- First Posted Date
- 2018-02-01
- Last Posted Date
- 2025-02-10
- Lead Sponsor
- University Health Network, Toronto
- Target Recruit Count
- 50
- Registration Number
- NCT03418818
- Locations
- 🇨🇦
University Health Network, Toronto, Ontario, Canada
A Study to Determine the Value of 18F-FAZA PET Imaging in Patients With Breast Cancer
Phase 2
Terminated
- Conditions
- Breast Neoplasm
- Interventions
- Drug: FluGlucoScan Injection (18F-FDB) PET scan
- First Posted Date
- 2008-10-13
- Last Posted Date
- 2019-08-22
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 23
- Registration Number
- NCT00771381
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
[18]F-FAZA PET Imaging Study in Patients With Cancer of the Head & Neck, Lung, Renal Cell, Brain, Lymphoma and Neuroendocrine Tumours
Phase 1
Terminated
- Conditions
- Neuroendocrine TumoursRenal Cell Carcinoma
- Interventions
- First Posted Date
- 2006-05-09
- Last Posted Date
- 2019-08-26
- Lead Sponsor
- AHS Cancer Control Alberta
- Target Recruit Count
- 92
- Registration Number
- NCT00323076
- Locations
- 🇨🇦
Cross Cancer Institute, Edmonton, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath